Niaudet 1990.

Methods	Study design: parallel RCT Study duration: September 1987 to May 1988 Study follow‐up: not reported
Participants	Country: France Setting: single centre Inclusion criteria: children, 1st DD kidney transplant recipients Number: treatment group 1 (14); treatment group 2 (14) Mean age ± SD (years): not reported Sex (M/F): not reported Exclusion criteria: not reported
Interventions	Treatment group 1 OKT3 (Cilag): 1 mL/10 kg up to 40 kg, 5 mL if over 40 kg, given for 21 days Given via peripheral vein over 2 min, 1st dose prior to reperfusion Treatment group 2 ALG (Merieux) 1mL/kg via AVF or CVC via IV infusion over 12 h; given for 21 days Immunosuppression (both groups) AZA: 0.75 to 1.5 mg/kg/d PRED: 60 mg/m2/d, tapered to 30 mg/m2 by day 30 CSA: 150 mg/m2 from day 18, adjusted to maintain level 100 to 200 ng/mL
Outcomes	Patient survival Graft survival Acute rejection Infection Other side effects
Notes	No table 1, states similar for age, sex, previous blood transfusions, HLA, PRA, cold ischaemia time There was also a 2nd part to paper about high dose versus low dose OKT3. There was limited info but low and high dose groups did not appear to be randomised. This data therefore not included Funding source: not reported
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Insufficient information to permit judgement
Allocation concealment (selection bias)	Unclear risk	Insufficient information to permit judgement
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Unlikely to influence outcomes
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Unlikely to influence outcomes
Incomplete outcome data (attrition bias) All outcomes	Low risk	All patient outcome data reported
Selective reporting (reporting bias)	Low risk	All expected outcomes reported
Other bias	Unclear risk	Funding source not reported